The frequency of macroprolactinemia among patients with hyperprolactinemia in a central laboratory of a training and research hospital.

Northern clinics of Istanbul Pub Date : 2024-11-21 eCollection Date: 2024-01-01 DOI:10.14744/nci.2023.94758
Nilufer Bayraktar
{"title":"The frequency of macroprolactinemia among patients with hyperprolactinemia in a central laboratory of a training and research hospital.","authors":"Nilufer Bayraktar","doi":"10.14744/nci.2023.94758","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Macroprolactinemia is a well-described endocrine disorder, with its results leading to unnecessary tests and overtreatment. However, routine macroprolactin screening is not performed in many laboratories. Routinely used prolactin assays can result in false diagnosis of hyperprolactinemia in patients with no signs and symptoms related to hyperprolactinemia and clinicians should be aware of macroprolactinemia frequency encountered with the method in use. In this study, it was aimed to examine the frequency of macroprolactinemia among patients with hyperprolactinemia.</p><p><strong>Methods: </strong>Prolactin analyses were performed on Roche Cobas<sup>®</sup> e801 immunoanalyzer using the Elecsys Prolactin II electrochemiluminesence immunoassay (Roche Diagnostics, Mannheim, Germany). Samples were provided from 14 different hospitals in total and evaluated with the same method in a single central laboratory. In order to precipitate the samples for macroprolactin analysis, polyethylene glycol (PEG) 6000 was used.</p><p><strong>Results: </strong>In this study, we evaluated 1100 patients with hyperprolactinemia and determined the frequency of macroprolactinemia to be 9.6% (recovery cut-off value <40%), while 8.5% of the patients were in the gray zone (recovery cut-off value 40% to <60%).</p><p><strong>Conclusion: </strong>Laboratories should consider regularly screening for macroprolactinemia in all hyperprolactinemic samples and collaborate with clinicians to raise awareness about the prevalence of this condition.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"11 6","pages":"520-524"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622756/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2023.94758","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Macroprolactinemia is a well-described endocrine disorder, with its results leading to unnecessary tests and overtreatment. However, routine macroprolactin screening is not performed in many laboratories. Routinely used prolactin assays can result in false diagnosis of hyperprolactinemia in patients with no signs and symptoms related to hyperprolactinemia and clinicians should be aware of macroprolactinemia frequency encountered with the method in use. In this study, it was aimed to examine the frequency of macroprolactinemia among patients with hyperprolactinemia.

Methods: Prolactin analyses were performed on Roche Cobas® e801 immunoanalyzer using the Elecsys Prolactin II electrochemiluminesence immunoassay (Roche Diagnostics, Mannheim, Germany). Samples were provided from 14 different hospitals in total and evaluated with the same method in a single central laboratory. In order to precipitate the samples for macroprolactin analysis, polyethylene glycol (PEG) 6000 was used.

Results: In this study, we evaluated 1100 patients with hyperprolactinemia and determined the frequency of macroprolactinemia to be 9.6% (recovery cut-off value <40%), while 8.5% of the patients were in the gray zone (recovery cut-off value 40% to <60%).

Conclusion: Laboratories should consider regularly screening for macroprolactinemia in all hyperprolactinemic samples and collaborate with clinicians to raise awareness about the prevalence of this condition.

求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信